ALAMEDA, Calif. and BARCELONA, Spain, May 31, 2016 /PRNewswire/ -- Singulex, Inc., the leader in next generation immunodiagnostic technology powered by single molecule counting, announced today a partnership with Grifols, one of the world's largest plasma product manufacturers and a pioneer in the research and development of therapeutic alternatives designed to contribute to scientific development. Grifols has subscribed a share capital increase and holds a 20% stake in Singulex. The partnership provides Singulex US$50 million in exchange for Grifols' access to an exclusive worldwide license for the use and sale of Singulex' SMC technology for the screening of donor blood and plasma. Grifols' investment marks a major advancement in further ensuring the safety of blood and plasma products.
"Singulex is pleased that Grifols has made this significant investment in Singulex and our SMC technology platform," said Guido Baechler, president and chief executive officer, Singulex. "Our technology already has the power to provide definitive answers for physicians and patients for improved health outcomes and is backed by extensive peer-reviewed publication and industry adoption. This new partnership will help us shape and develop the future of blood screening technology and make major advancements in the safety of next generation blood products."
Single molecule counting technology, developed by Singulex for clinical diagnostic and scientific discovery, has the power to identify biomarkers of diseases that were previously undetectable. Applying this technology to blood screenings will allow for greater diagnostic sensitivity, accuracy and efficiency to ensure the safe capture and processing of blood and plasma products.
"As one of the world's leaders in the manufacturing of plasma products to treat a variety of rare, chronic and life-threatening conditions, safety and screening of donated human blood and plasma is critical for Grifols," said Carsten Schroeder, President of the Grifols Diagnostic Division. "Singulex' SMC technology and leadership in next generation immunodiagnostics presents Grifols with the diagnostic sensitivity, accuracy and reliability to develop more advanced blood screening platforms."
Singulex has developed the Sgx Clarity™ System, a fully-automated in vitro diagnostics system that will soon bring the proven SMC technology to hospital and reference laboratories worldwide. Singulex also provides clinical laboratory testing services which enhance early detection of cardiac and vascular disorders.
About Singulex, Inc.
Singulex is the next generation immunodiagnostic company developing Single Molecule Counting technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC™ technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive lab testing services are transforming patient care from reactive disease treatment to proactive health management.
The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex has developed the Sgx Clarity™ System, a fully-automated in vitro diagnostics system that will bring the benefits of SMC technology to hospital and reference labs worldwide. For more information, please visit www.singulex.com.
Grifols is a global healthcare company with more than 75-year legacy of improving people's health and well-being through the development of protein therapies, hospital pharmacy products and diagnostic technology for clinical use.
The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 160 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines. As a recognized leader in transfusion medicine, Grifols offers a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks, and transfusion centers.
In 2015, sales exceeded 3,934 million euros with a headcount close to 14,700 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.
The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com.
SOURCE Singulex, Inc.